Tags » Incyte

Investigational baricitinib superior to methotrexate monotherapy in achveing clinical remission

Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were superior to methotrexate monotherapy in helping patients achieve clinical remission. 594 more words


Eli Lilly, Incyte: positive top-line results of RA-BEGIN

Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). 427 more words

North America